Welcome to our dedicated page for ALTERITY THERAPEUTICS SEC filings (Ticker: PRNAF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alterity Therapeutics Ltd. filings document a foreign private issuer and development-stage biotechnology company focused on disease-modifying treatments for neurodegenerative diseases. Its Form 6-K reports provide current updates on the company’s Multiple System Atrophy program, including ATH434, the bioMUSE Natural History Study, quantitative MRI biomarker research, medical meeting presentations, and clinical or regulatory program activity.
The filing record also includes Appendix 4C quarterly cash-flow and corporate activity reports, exhibits incorporated by reference into Form S-8 and Form F-3 registration statements, governance updates, and notices related to securities matters such as consolidation or split activity. These filings describe the company’s operating progress, financing framework, board and management disclosures, risk-related development context, and capital-structure records.
ALTERITY THERAPEUTICS LTD (ATHE) director Peter Ashley Marks reported related transactions on August 31, 2026 through Lampam Pty Ltd. An entity associated with him bought 47,620 ordinary shares at $0.50 per share, bringing its indirect holdings to 191,340 ordinary shares, and disposed of 47,620 listed options with a $0.50 exercise price expiring August 31, 2026.
ALTERITY THERAPEUTICS LTD (ATHE) reported that Chief Executive Officer and director David Allen Stamler recorded a disposition involving derivative securities tied to the company’s ordinary shares. On August 31, 2026, he reported a transaction in 47,620 listed options expiring August 31, 2026 at a reported price of $0.50 per option, with 47,620 underlying ordinary shares. Following the transaction, this listed option position is shown as 0 derivative securities held directly.
Alterity Therapeutics Limited (ATHE) reports that it has completed the issue of 8,400,000 fully paid ordinary shares to MST Financial Services Pty Ltd and various sub-underwriters. The shares were issued pursuant to an underwriting agreement relating to Alterity’s ATHO class of listed options exercisable at A$0.50 each on or before August 31, 2026.
The company has provided a cleansing notice under section 708A(5)(e) of the Corporations Act 2001 (Cth), which facilitates secondary trading of these newly issued shares in compliance with Australian securities law.
ALTERITY THERAPEUTICS LTD (ATHE) reports that CEO David Stamler, M.D., will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 on September 11, 2026 at 10:20 a.m. ET, with a live and archived webcast available via the company’s investor website.
Alterity is a clinical stage biotechnology company developing disease modifying therapies for neurodegenerative diseases, focusing on Multiple System Atrophy and related Parkinsonian disorders. The company is preparing to initiate a Phase 3 pivotal trial of its lead asset ATH434, which has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and positive data in an open label Phase 2 trial in advanced MSA.
ALTERITY THERAPEUTICS LTD (ATHE) entered into an Underwriting Agreement with MST Financial Services Pty Ltd, which has agreed to underwrite the exercise of up to 8,400,000 unexercised ATHO listed options ahead of their expiry. These Underwritten Options are expected to raise approximately A$4.2 million before costs.
There are currently 15,918,235 ATHO options on issue, exercisable at A$0.50 and expiring at 5:00pm (AEST) on 31 August 2026. Subject to completion of the underwriting and depending on how many options are exercised by holders, Alterity will issue between 8,400,000 and 15,918,235 new shares and raise approximately A$4.2–7.96 million before costs.
The underwriter will receive a 7% fee on gross proceeds from underwritten option exercises and may allocate Underwritten Shares to sub-underwriters that are sophisticated and professional investors. Proceeds are expected to support late-stage clinical development of ATH434 in Multiple System Atrophy and general working capital. The agreement includes customary conditions and termination events and may be terminated by either party in specified circumstances.
ALTERITY THERAPEUTICS LIMITED (ATHE) filed an annual report describing its development-stage neurology business focused on ATH434 for multiple system atrophy (MSA) and other Parkinsonian disorders. ATH434 is the lead and highly concentrated asset; Alterity reported positive FDA feedback and End‑of‑Phase 2 alignment on key elements of a registrational Phase 3 program.
The company’s ordinary shares trade primarily on the ASX and its American Depositary Shares, each representing 12 ordinary shares, trade on the Nasdaq Capital Market under “ATHE.” Ordinary shares outstanding were 217,508,862 as of June 30, 2026. Financial statements are prepared in Australian dollars under IFRS.
Alterity reported operating losses of A$23.4 million in fiscal 2026 and A$12.1 million in 2025, with operating cash outflows of A$22.5 million and A$11.5 million, and expects continued losses and substantial additional capital needs. The report highlights extensive clinical, regulatory, manufacturing, data‑privacy, intellectual property, healthcare policy, currency, listing‑compliance, geopolitical and Australian‑jurisdiction risks, including PFIC tax risk for certain U.S. holders and potential dilution from future financings.